Severe Combined Immunodeficiency Clinical Trials

3 recruiting

About Severe Combined Immunodeficiency Clinical Trials

Looking for clinical trials for Severe Combined Immunodeficiency? There are currently 3 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Severe Combined Immunodeficiency trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Severe Combined Immunodeficiency clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting

Genetic Basis of Immunodeficiency

Severe Combined Immunodeficiency
National Heart, Lung, and Blood Institute (NHLBI)100 enrolled1 locationNCT00055172
Recruiting
Phase 1Phase 2

Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

X-linked Severe Combined Immunodeficiency (XSCID)
National Institute of Allergy and Infectious Diseases (NIAID)40 enrolled1 locationNCT01306019
Recruiting
Phase 1Phase 2

Safety and Efficacy Study of Transplantation of Autologous CD34+ Cells Transduced With the G2ARTE Lentiviral Vector Expressing the DCLRE1C cDNA in Artemis (DCLRE1C) Deficient Severe Combined Immunodeficiency Patients (ARTEGENE)

Artemis (DCLRE1C ) Deficient Severe Combined Immunodeficiency
Assistance Publique - Hôpitaux de Paris7 enrolled1 locationNCT05071222
Recruiting
Phase 1Phase 2

Autologous Gene Therapy for Artemis-Deficient SCID

Severe Combined Immunodeficiency
University of California, San Francisco24 enrolled1 locationNCT03538899
Recruiting

Study of Populations at Risk of Developing Chronic Hepatitis Linked to Chronic Enteric Virus Infection in Patients With Primary Immunodeficiency and Secondary Humoral Deficiency

Humoral Primary Immunodeficiencies (PIDs)Secondary Form of Humoral ImmunodeficienciesCombined Immunodeficiency (CID)+1 more
Assistance Publique - Hôpitaux de Paris120 enrolled3 locationsNCT06659588
Recruiting
Not Applicable

Gene Therapy for ADA-SCID Using an Improved Lentiviral Vector (Ivlv-ADA)

Adenosine DeAminase Severe Combined ImmunoDeficiency (ADA-SCID)
Shenzhen Geno-Immune Medical Institute10 enrolled2 locationsNCT03645460
Recruiting
Not Applicable

Phase I/II Clinical Trial Stem Cell Gene Therapy in RAG1-Deficient SCID

Severe Combined Immunodeficiency Due to RAG1 Deficiency
Leiden University Medical Center10 enrolled7 locationsNCT04797260
Recruiting
Phase 1

Lentiviral Gene Therapy for X-linked Severe Combined Immunodeficiency

Severe Combined Immunodeficiency, X-Linked
Great Ormond Street Hospital for Children NHS Foundation Trust5 enrolled1 locationNCT03601286
Recruiting

The Experience of Screening for SCID

Severe Combined Immunodeficiency
King's College London90 enrolled1 locationNCT05651113